Showing 121-130 of 327 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Generation of vascularized, transplantable islets from human iPSC-derived beta and isogenic vasculogenic cells | The Regents of the University of California, San Francisco | Julie Sneddon | Cures | 01-July-2024 to 30-June-2026 | $600.000,00 |
| Mechanistic Etiologies Underlying the Impact of Verapamil to Preserve β Cell Function in Type 1 diabetes | Regents of the University of Minnesota | Antoinette Moran | Cures | 01-September-2024 to 31-August-2026 | $643.946,00 |
| A hybrid effectiveness implementation trial of an intervention to reduce diabetes-specific emotional distress. | Ann & Robert H. Lurie Children’s Hospital of Chicago | Jill Weissberg-Benchell | Improving Lives | 01-September-2024 to 31-August-2029 | $1.936.551,00 |
| Targeting sub-micron ultrasound contrast agents to the immune-infiltrated islet microenvironment in Type1 diabetes | Regents of the University of Colorado | Richard Benninger | Cures | 01-July-2024 to 30-June-2027 | $900.000,00 |
| Achieving Health in Emerging Adults with Diabetes Program | Seattle Childrens Hospital | Faisal Malik | Improving Lives | 01-September-2024 to 31-August-2028 | $1.734.029,00 |
| Inhibition of REDD1 Allostery as a Therapeutic for Type 1 Diabetes | Penn State College of Medicine | Michael Dennis | Improving Lives | 01-June-2024 to 31-May-2026 | $200.000,00 |
| Determining the role of new genes that may be involved in Type 1 Diabetes Pathogenesis | Beth Israel Deaconess Medical Center Inc | Ismail Syed | Cures | 01-June-2024 to 31-October-2025 | $199.999,67 |
| Investigation of AKS-107 immunotherapeutic in mice and human cells | Vanderbilt University Medical Center (VUMC) | Rachel Bonami | Cures | 01-July-2024 to 30-June-2027 | $800.000,00 |
| Promoting functional maturation of SC-derived beta-cells by novel Epigenetic regulators | University of Washington | Vincenzino Cirulli | Cures | 01-October-2024 to 30-September-2026 | $500.000,00 |
| microRNA-146a is a potential therapeutic target for type 1 diabetes | Case Western Reserve University | Parameswaran Ramakrishnan | Cures | 01-June-2024 to 31-May-2027 | $600.000,00 |